DUPIXENT®
(dupilumab) Injection
100mg · 200mg · 300mg

DOSAGE & ADMINISTRATION

DUPIXENT DOSING IN 3 DISEASES WHERE TYPE 2 INFLAMMATION IS ONE OF THE KEY DRIVERS OF PATHOPHYSIOLOGY[1,2]

ATOPIC DERMATITIS

Patients 6+ years

DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

ASTHMA

Patients 6+ years

DUPIXENT is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.

CRSwNP

Patients 18+ years

DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).

Inflammation driven by IL-4 and IL-13 is an important component in the pathogenesis of asthma, atopic dermatitis, and CRSwNP[1]

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Please see additional Important Safety Information throughout and click here for full Prescribing Information.

DOSAGE FOR UNCONTROLLED MODERATE-TO-SEVERE ATOPIC DERMATITIS

ADULTS (18+ years)[1]

One-dose regimen

Sample prescription for a 300 mg dose Q2W

DUPIXENT® (dupilumab)
300 mg/2 mL PRE-FILLED PEN OR SYRINGE 2-PACK

INITIAL DOSE: **600 mg** — # OF 2-PACKS QTY: 1

Sig: 2 injections subcutaneously on **Day 1**
(BOTH PRE-FILLED PENS OR SYRINGES OF THE 2-PACK)

MAINTENANCE DOSE: **300 mg** — # OF 2-PACKS QTY: 1 — REFILLS _____

Sig: 1 injection **2 weeks** after on **Day 15**
(1ST PRE-FILLED PEN OR SYRINGE OF THE 2-PACK)

and **1** injection **2 weeks** after on **Day 29**
(2ND PRE-FILLED PEN OR SYRINGE OF THE 2-PACK)
and every **2 weeks** thereafter

1 refill provides 4 weeks of maintenance therapy.

Q2W, once every 2 weeks.

Choice of administration: Available in a 200 mg and 300 mg pre-filled pen for appropriate patients (12+ years) or syringe[1]

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT compared to those who received placebo, with conjunctivitis being the most frequently reported eye disorder. Conjunctivitis also occurred more frequently in chronic rhinosinusitis with nasal polyposis subjects who received DUPIXENT compared to those who received placebo. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in atopic dermatitis patients. Some patients reported visual disturbances (e.g. blurred vision) associated with conjunctivitis or keratitis. Advise patients to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.

Eosinophilic Conditions: Patients being treated for asthma may present with serious systemic eosinophilia sometimes presenting with clinical features of eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis (EGPA), conditions which are often treated with systemic corticosteroid therapy.

Please see additional Important Safety Information throughout and click here for full Prescribing Information.

PEDIATRIC PATIENTS (6-17 years)[1,a]

Weight-tiered dosing regimen



[a] The DUPIXENT 200 mg and 300 mg Pre-filled Pens are approved for patients aged 12+ years.[1]
[b] 60 kg is equal to 132 lb.
[c] 30 kg is equal to 66 lb.
[d] 15 kg is equal to 33 lb.

Sample prescription for a 300 mg dose Q4W[e]

DUPIXENT® (dupilumab)
300 mg/2 mL PRE-FILLED SYRINGE 2-PACK

INITIAL DOSE: **600 mg** — # OF 2-PACKS QTY: 1

Sig: 2 injections subcutaneously on **Day 1**
(BOTH PRE-FILLED SYRINGES OF THE 2-PACK)

MAINTENANCE DOSE: **300 mg** — # OF 2-PACKS QTY: 1 — REFILLS _____

Sig: 1 injection **4 weeks** after on **Day 29**
(1ST PRE-FILLED SYRINGE OF THE 2-PACK)

and **1** injection **4 weeks** after on **Day 57**
(2ND PRE-FILLED SYRINGE OF THE 2-PACK)
and every **4 weeks** thereafter

1 refill provides 8 weeks of maintenance therapy.

[e] For pediatric patients 15 kg to <30 kg.
Q4W, once every 4 weeks.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

Eosinophilic Conditions (cont'd): These events may be associated with the reduction of oral corticosteroid therapy. Healthcare providers should be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients with eosinophilia.

DUPIXENT® (dupilumab) Injection
100mg · 200mg · 300mg

DOSAGE FOR MODERATE-TO-SEVERE ASTHMA

ADULTS & PEDIATRIC PATIENTS (12+ years)[1]



For patients with OCS-dependent asthma or patients with comorbid moderate-to-severe atopic dermatitis or adults with comorbid CRSwNP

- Initial dose is 600 mg (two 300 mg pre-filled pens or syringes) followed by every-2-week dosing of a 300 mg pre-filled pen or syringe[1]

Sample prescription for a 300 mg dose Q2W

DUPIXENT® (dupilumab)
300 mg/2 mL PRE-FILLED PEN OR SYRINGE 2-PACK

INITIAL DOSE: **600 mg** — # OF 2-PACKS QTY: 1

Sig: 2 injections subcutaneously on **Day 1**
(BOTH PRE-FILLED PENS OR SYRINGES OF THE 2-PACK)

MAINTENANCE DOSE: **300 mg** — # OF 2-PACKS QTY: 1 — REFILLS _____

Sig: 1 injection **2 weeks** after on **Day 15**
(1ST PRE-FILLED PEN OR SYRINGE OF THE 2-PACK)

and **1** injection **2 weeks** after on **Day 29**
(2ND PRE-FILLED PEN OR SYRINGE OF THE 2-PACK)
and every **2 weeks** thereafter

1 refill provides 4 weeks of maintenance therapy.

OCS, oral corticosteroid.

Choice of administration: Available in a 200 mg and 300 mg pre-filled pen for appropriate patients (12+ years) or syringe[1]

PEDIATRIC PATIENTS (6-11 years)[1]

Weight-tiered dosing regimen



NO LOADING DOSE IS RECOMMENDED FOR THESE PEDIATRIC DOSING SCHEDULES

For pediatric patients (6 to 11 years old) with asthma and comorbid moderate-to-severe atopic dermatitis, follow the recommended dosage for pediatric patients with moderate-to-severe atopic dermatitis, which includes an initial loading dose.

[a] 30 kg is equal to 66 lb.
[b] 15 kg is equal to 33 lb.
[c] A DUPIXENT Pre-Filled Pen will not be available for the 100 mg dose.

Sample prescription for a 200 mg dose Q2W (no loading dose)

DUPIXENT® (dupilumab)
200 mg/1.14 mL PRE-FILLED SYRINGE 2-PACK

MAINTENANCE DOSE: **200 mg** — # OF 2-PACKS QTY: 1 — REFILLS _____

Sig: 1 injection subcutaneously on **Day 1**
(1ST PRE-FILLED SYRINGE OF THE 2-PACK)

and **1** injection
(2ND PRE-FILLED SYRINGE OF THE 2-PACK)
every **2 weeks** thereafter

1 refill provides 4 weeks of maintenance therapy.

ASTHMA

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

Eosinophilic Conditions (cont'd): Cases of eosinophilic pneumonia were reported in adult subjects who participated in the asthma development program and cases of vasculitis consistent with EGPA have been reported with DUPIXENT in adult subjects who participated in the asthma development program as well as in adult subjects with co-morbid asthma in the CRSwNP development program. A causal association between DUPIXENT and these conditions has not been established.

Please see additional Important Safety Information throughout and click here for full Prescribing Information.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

Acute Asthma Symptoms or Deteriorating Disease: Do not use DUPIXENT to treat acute asthma symptoms, acute exacerbations, acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of DUPIXENT.

DUPIXENT® (dupilumab) Injection
100mg · 200mg · 300mg

DOSAGE FOR INADEQUATELY CONTROLLED CRSwNP

ADULTS (18+ years)[1]

One-dose regimen



1 pre-filled pen or syringe

NO LOADING DOSE

Sample prescription for a 300 mg dose Q2W (no loading dose)

DUPIXENT® (dupilumab)
300 mg/2 mL PRE-FILLED PEN OR SYRINGE 2-PACK

MAINTENANCE DOSE:	# OF 2-PACKS	REFILLS
300 mg	QTY: 1	_____

Sig: 1 injection subcutaneously on **Day 1**
(1ST PRE-FILLED PEN OR SYRINGE OF THE 2-PACK)

and **1** injection
(2ND PRE-FILLED PEN OR SYRINGE OF THE 2-PACK)
every **2 weeks** thereafter

1 refill provides 4 weeks of maintenance therapy.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Patients with Co-morbid Asthma: Advise patients with atopic dermatitis or CRSwNP who have co-morbid asthma not to adjust or stop their asthma treatments without consultation with their physicians.

Arthralgia: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

Please see additional Important Safety Information throughout and click here for full Prescribing Information.

GETTING YOUR PATIENTS STARTED WITH DUPIXENT

DUPIXENT MyWay® provides support to patients to help enable access to DUPIXENT:

NURSING SUPPORT

- *DUPIXENT MyWay* takes a patient-centric approach to educating and empowering patients to start and stay on track with DUPIXENT

COVERAGE SUPPORT

- Our team will provide assistance navigating the insurance process

PATIENT ACCESS SUPPORT[a]

- *DUPIXENT MyWay* support resources can help your patients access DUPIXENT
- Eligible patients covered by commercial health insurance may pay as little as **$0[b] copay** per fill of DUPIXENT (maximum of $13,000 per patient per calendar year)

You can enroll your patients in *DUPIXENT MyWay* by calling 1-844-DUPIXEN(T) or by visiting DupixentHCP.com/MyWay and completing the Enrollment Form

~98% **OF COMMERCIALLY INSURED PATIENTS NATIONALLY ARE COVERED FOR DUPIXENT[3,c,d]**

[a] Eligible patients subject to program restrictions.
[b] Approval is not guaranteed. Program has an annual maximum of $13,000. **THIS IS NOT INSURANCE.** Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or other federal or state programs including any state pharmaceutical assistance programs. This program is not valid where prohibited by law, taxed or restricted. *DUPIXENT MyWay* reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Any savings provided by the program may vary depending on patients' out-of-pocket costs. The program is intended to help patients afford DUPIXENT. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program. In those situations, the program may change its terms. Additional terms and conditions apply.
[c] MMIT Lives as of November 2021. [d] Coverage varies by type and plan.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves. Helminth infections (5 cases of enterobiasis and 1 case of ascariasis) were reported in pediatric patients 6 to 11 years old in the pediatric asthma development program.

Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines in patients treated with DUPIXENT.

DUPIXENT® (dupilumab) Injection
100mg · 200mg · 300mg

AT-HOME OR IN-OFFICE ADMINISTRATION OPTIONS

PRE-FILLED PEN (12+ YEARS)[1,4]

- Subcutaneous autoinjector with hidden needle
- Needle cap is not made with natural rubber latex
- Visual and audible feedback
- Available in 200 mg and 300 mg

PRE-FILLED SYRINGE[1,5]

- Subcutaneous injection with needle shield
- Includes finger grip
- Visual feedback
- Available in 100 mg, 200 mg, and 300 mg*

*200 mg and 300 mg shown.

How to take DUPIXENT[1]

- DUPIXENT is intended for use under the guidance of a healthcare provider
- A patient may self-inject DUPIXENT after receiving training in subcutaneous injection technique using the pre-filled syringe or pre-filled pen. The DUPIXENT pre-filled pen is only for use in adults and pediatric patients aged 12 years and older
  - In pediatric patients 12 years of age and older, it is recommended that DUPIXENT be given under the supervision of an adult
  - In pediatric patients 6 to 11 years of age, the DUPIXENT pre-filled syringe should be given by a caregiver
  - Provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT prior to use, according to the Instructions for Use
- DUPIXENT can be administered in the office under the guidance of a healthcare provider if the patient is not an appropriate candidate for at-home administration

Missed Dose Information

- If an every-other-week dose is missed, instruct the patient to administer the injection within 7 days from the missed dose and then resume the original schedule. If the missed dose is not administered within 7 days, instruct the patient to wait until the next dose on the original schedule
- If an every-4-week dose is missed, instruct the patient to administer the injection within 7 days from the missed dose and then resume the original schedule. If the missed dose is not administered within 7 days, instruct the patient to administer the dose, starting a new schedule based on this date

Please see additional Important Safety Information throughout and click here for full Prescribing Information.

Specific to moderate-to-severe atopic dermatitis[1]

- DUPIXENT can be used with or without topical corticosteroids. Topical calcineurin inhibitors may be used, but should be reserved for problem areas only, such as the face, neck, and intertriginous and genital areas

Administer at different injection sites[1]

- Atopic dermatitis and adult and adolescent asthma patients: For the initial dose, administer each of the 2 injections at different injection sites
- Administer the subcutaneous injection into the thigh or abdomen, except for the 2 inches (5 cm) around the navel
- The upper arm can also be used if a caregiver administers the injection
- Rotate the injection site with each injection. DO NOT inject DUPIXENT into skin that is tender, damaged, bruised, or scarred



How DUPIXENT is supplied[1]

DUPIXENT is available in cartons containing 2 single-dose pre-filled pens with hidden needle or 2 single-dose pre-filled syringes with needle shield. The pre-filled pen is designed to deliver 300 mg of DUPIXENT in a 2 mL solution or 200 mg in a 1.14 mL solution. The pre-filled syringe is designed to deliver 300 mg of DUPIXENT in a 2 mL solution, 200 mg in a 1.14 mL solution, or 100 mg in a 0.67 mL solution.

DUPIXENT prescriptions can be filled at select retail pharmacies or through specialty pharmacies, which can ship medication directly to patients.

There is no requirement for initial lab testing or ongoing lab monitoring, according to the DUPIXENT Prescribing Information.

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS:

- **Atopic dermatitis:** The most common adverse reactions (incidence ≥1% at Week 16) in adult patients are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye. The safety profile in children and adolescents through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT in adolescents and children observed through Week 52 was consistent with that seen in adults with atopic dermatitis.
- **Asthma:** The most common adverse reactions (incidence ≥1%) are injection site reactions, oropharyngeal pain, and eosinophilia.

DUPIXENT® (dupilumab) Injection
100mg · 200mg · 300mg

DUPIXENT OFFERS MULTIPLE ADMINISTRATION OPTIONS FOR YOU AND YOUR PATIENTS

AT-HOME ADMINISTRATION

IN-OFFICE ADMINISTRATION



PRE-FILLED PEN (ages 12+ years)[1] OR SYRINGE

Visit *DUPIXENTHCP.COM* for more information

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS (cont'd):

- **Chronic rhinosinusitis with nasal polyposis:** The most common adverse reactions (incidence ≥1%) are injection site reactions, eosinophilia, insomnia, toothache, gastritis, arthralgia, and conjunctivitis.

USE IN SPECIFIC POPULATIONS

- **Pregnancy:** A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to **https://mothertobaby.org/ongoing-study/dupixent/**. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
- **Lactation:** There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

Please see additional Important Safety Information throughout and click here for full Prescribing Information.

References: 1. DUPIXENT Prescribing Information. **2.** Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. *Nat Rev Drug Discov.* 2016;15(1):35-50. **3.** The Dedham Group Quality of Access Tracking Report. November 2021. **4.** DUPIXENT 200 mg/300 mg Pre-filled Pen Instructions for Use. **5.** DUPIXENT 100 mg/200 mg/300 mg Pre-filled Syringe Instructions for Use.

DUPIXENT® (dupilumab) Injection
100mg · 200mg · 300mg

SANOFI GENZYME

REGENERON

DUP.21.11.0559 02/2022